UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Follicular lymphoma: evolving therapeutic strategies

Blood, 2016-04, Vol.127 (17), p.2055-2063

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Blood, 2014-05, Vol.123 (19), p.2944-2952

2014

Link zum Volltext

Verfügbarkeit prüfen

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1329-1338

2021

Link zum Volltext

Verfügbarkeit prüfen

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Blood, 2018-09, Vol.132 (10), p.1013-1021

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Blood, 2012-10, Vol.120 (16), p.3280-3287

2012

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4867-4874

2006

Link zum Volltext

Verfügbarkeit prüfen

Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma

Journal of clinical oncology, 2013-02, Vol.31 (6), p.692-700

2013

Link zum Volltext

Verfügbarkeit prüfen

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Blood, 2013-05, Vol.121 (18), p.3547-3553

2013

Link zum Volltext

Verfügbarkeit prüfen

Recent Advances in Antibody Drug Conjugates for Lymphoma

Oncology (Williston Park, N.Y.), 2020-12, Vol.34 (12), p.522-534

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3119-3126

2012

Link zum Volltext

Verfügbarkeit prüfen

Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?

Journal of clinical oncology, 2023-02, Vol.41 (4), p.724-726

Kahl, Brad S

2023

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

British journal of haematology, 2013-04, Vol.161 (1), p.76-86

2013

Link zum Volltext

Verfügbarkeit prüfen

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Blood, 2010-08, Vol.116 (7), p.1025-1034

2010

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3389-3395

2011

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans

JNCI : Journal of the National Cancer Institute, 2016-11, Vol.108 (11), p.djw145

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1741-1746

2007

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

American journal of hematology, 2023-02, Vol.98 (2), p.300-308

2023

Link zum Volltext

Verfügbarkeit prüfen

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Leukemia & lymphoma, 2023-04, Vol.64 (5), p.1026-1034

2023

Link zum Volltext

Verfügbarkeit prüfen

Long‐term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow‐up

HemaSphere, 2022-05, Vol.6 (5), p.e712-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

An iatrogenic orphan?

Blood, 2019-10, Vol.134 (16), p.1273-1274

Kahl, Brad S.

2019

Link zum Volltext

Verfügbarkeit prüfen

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Cancers, 2021-06, Vol.13 (11), p.2828

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 563

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(546)
Mit Volltextzugriff
(521)

Publikationsform

Sprache

Englisch
(561)
Japanisch
(21)
Polnisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(221)
Science & Technology
(221)
Humans
(208)
Hematology
(138)
Oncology
(123)
Male
(104)
Female
(102)
Middle Aged
(102)
Aged
(98)
Adult
(95)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(74)
Aged, 80 And Over
(64)
Treatment Outcome
(64)
Rituximab
(59)
Lymphoma
(47)
Prognosis
(39)
Disease-Free Survival
(34)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(32)
Antineoplastic Agents - Therapeutic Use
(31)
Lymphoma, Mantle-Cell - Drug Therapy
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(222)
Journal Of Clinical Oncology
(62)
Clinical Lymphoma, Myeloma And Leukemia
(27)
Leukemia & Lymphoma
(27)
Clinical Advances In Hematology & Oncology
(23)
Blood Advances
(18)
British Journal Of Haematology
(17)
Cancer
(11)
Haematologica
(10)
American Journal Of Hematology
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Follicular lymphoma: evolving therapeutic strategies

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Recent Advances in Antibody Drug Conjugates for Lymphoma

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499

Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

Long‐term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow‐up

An iatrogenic orphan?

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Suchergebnisse filtern